Tempest Therapeutics, Inc. - Common Stock TPST 深 沪
等待开盘 10-04 09:30:00 美东时间
10.40
-0.370
-3.44%
华盛通- 最 高10.89
- 今 开10.62
- 成交量 3.02万股
- 最 低 10.30
- 昨 收 10.77
- 总市值 3661.11万
- 52周最高 20.67
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 5.3495
- 委 比 49.07%
- 总股本 352.03万
- 历史最高 3381.30
- 量 比 0.74
- 振 幅 5.48%
- 历史最低 2.21
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多国元证券-电子行业周报：英伟达投资50亿美元入股英特尔，三星HBM3e通过英伟达验证-250922
（来源：研报虎） 报告要点： 本周(2025.9.15-2025.9.19)市场回顾 1)海外AI芯片指数本周下跌0.80%，本周成分股表现差异较大，M...
09-22 15:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Tempest Therapeutics Q2 EPS $(2.07) Beats $(3.23) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of $(3.23) by 35.91 percent. This is a 62.5 percent increase over losses of $(5.52) per share
08-12 04:22
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Received clearance to proceed with pivotal trial of amezalpat combination thera...
08-12 04:12
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
<p>Tempest Therapeutics received NMPA approval to initiate a pivotal trial for amezalpat in combination with atezolizumab and bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) in China. This approval builds on prior FDA and EMA clearances for the Phase 3 study, which aims to evaluate the efficacy of amezalpat against the current standard of care. HCC is a leading cause of cancer death globally, ...
06-30 12:00
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Tempest Therapeutics entered into a definitive agreement with a single institutional investor for a registered direct offering of 739,000 shares of its common stock at $6.25 per share, yielding approximately $4.6 million in gross proceeds. The funds will primarily support its strategic alternative process and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The offering is under a shelf registration statem...
06-11 12:00
Tempest Announces It Has Received Orphan Drug Designation From European Medicines Agency For Its Amezalpat For Treatment Of Patients With Hepatocellular Carcinoma
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were
06-05 20:08
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
Tempest Therapeutics announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to amezalpat, its oral small molecule PPAR⍺ antagonist, for the treatment of hepatocellular carcinoma (HCC). This designation follows positive results from a global Phase 1b/2 study showing superior outcomes, including a six-month improvement in overall survival, for amezalpat combination therapy compared to standard-of-care alone. HC...
06-05 12:00
Tempest Therapeutics Q1 EPS $(3.16) Beats $(3.71) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of $(3.71) by 14.82 percent. This is a 31.6 percent increase over losses of $(4.62) per share
05-14 04:45
美股大行评级 | 潜在涨幅506%！ JMP首予MBX Biosciences"跑赢大市"评级，目标价38美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117373634651086848.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Travere Therapeutics(TVTX)"买入"评级，目标价从45美元升至47美元</p> <p>• JMP证券：维持Benitec生物制药(BNTC)"跑赢大市"评级，
04-11 09:36
